156 related articles for article (PubMed ID: 38287125)
21. Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients.
Aoude LG; Bonazzi VF; Brosda S; Patel K; Koufariotis LT; Oey H; Nones K; Wood S; Pearson JV; Lonie JM; Arneil M; Atkinson V; Smithers BM; Waddell N; Barbour AP
Sci Rep; 2020 Oct; 10(1):17687. PubMed ID: 33077847
[TBL] [Abstract][Full Text] [Related]
22. Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program.
Diamantopoulos LN; Holt SK; Khaki AR; Sekar RR; Gadzinski A; Nyame YA; Vakar-Lopez F; Tretiakova MS; Psutka SP; Gore JL; Lin DW; Schade GR; Hsieh AC; Lee JK; Yezefski T; Schweizer MT; Cheng HH; Yu EY; True LD; Montgomery RB; Grivas P; Wright JL
Clin Genitourin Cancer; 2021 Apr; 19(2):144-154. PubMed ID: 33160889
[TBL] [Abstract][Full Text] [Related]
23. Identification of Prognostic Biomarkers of Cutaneous Melanoma Based on Analysis of Tumor Mutation Burden.
Lin J; Lin Y; Huang Z; Li X
Comput Math Methods Med; 2020; 2020():8836493. PubMed ID: 33273963
[TBL] [Abstract][Full Text] [Related]
24. Analysis of false multiple primary cancers: Hiroshima Tumor Tissue Registry's experience. Hiroshima Tumor Tissue Registry, Acting Committee.
Jpn J Clin Oncol; 1987 Sep; 17(3):197-204. PubMed ID: 3669363
[TBL] [Abstract][Full Text] [Related]
25. First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.
Ready N; Hellmann MD; Awad MM; Otterson GA; Gutierrez M; Gainor JF; Borghaei H; Jolivet J; Horn L; Mates M; Brahmer J; Rabinowitz I; Reddy PS; Chesney J; Orcutt J; Spigel DR; Reck M; O'Byrne KJ; Paz-Ares L; Hu W; Zerba K; Li X; Lestini B; Geese WJ; Szustakowski JD; Green G; Chang H; Ramalingam SS
J Clin Oncol; 2019 Apr; 37(12):992-1000. PubMed ID: 30785829
[TBL] [Abstract][Full Text] [Related]
26. A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients.
Tian Y; Xu J; Chu Q; Duan J; Zhang J; Bai H; Yang Z; Fang W; Cai L; Wan R; Fei K; He J; Gao S; Zhang L; Wang Z; Wang J
BMC Med; 2020 Aug; 18(1):232. PubMed ID: 32843031
[TBL] [Abstract][Full Text] [Related]
27. Attributes and survival patterns of multiple primary cutaneous malignant melanoma.
Gupta BK; Piedmonte MR; Karakousis CP
Cancer; 1991 Apr; 67(7):1984-9. PubMed ID: 2004315
[TBL] [Abstract][Full Text] [Related]
28. Impact of gender and primary tumor location on outcome of patients with cutaneous melanoma.
Voinea S; Blidaru A; Panaitescu E; Sandru A
J Med Life; 2016; 9(4):444-448. PubMed ID: 27928453
[No Abstract] [Full Text] [Related]
29. Risk of Melanoma Recurrence After Diagnosis of a High-Risk Primary Tumor.
von Schuckmann LA; Hughes MCB; Ghiasvand R; Malt M; van der Pols JC; Beesley VL; Khosrotehrani K; Smithers BM; Green AC
JAMA Dermatol; 2019 Jun; 155(6):688-693. PubMed ID: 31042258
[TBL] [Abstract][Full Text] [Related]
30. Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies.
Voutsadakis IA
Curr Oncol; 2022 Feb; 29(3):1390-1407. PubMed ID: 35323317
[No Abstract] [Full Text] [Related]
31. Genomic Alterations and Tumor Mutation Burden in Merkel Cell Carcinoma.
Brazel D; Kumar P; Doan H; Pan T; Shen W; Gao L; Moyers JT
JAMA Netw Open; 2023 Jan; 6(1):e2249674. PubMed ID: 36602798
[TBL] [Abstract][Full Text] [Related]
32. Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians.
Ademuyiwa FO; Tao Y; Luo J; Weilbaecher K; Ma CX
Breast Cancer Res Treat; 2017 Feb; 161(3):491-499. PubMed ID: 27915434
[TBL] [Abstract][Full Text] [Related]
33. The nucleosome remodeling and deacetylase complex has prognostic significance and associates with immune microenvironment in skin cutaneous melanoma.
Liu X; Wang J
Int Immunopharmacol; 2020 Nov; 88():106887. PubMed ID: 32799111
[TBL] [Abstract][Full Text] [Related]
34. Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations.
Liu YL; Cadoo KA; Mukherjee S; Khurram A; Tkachuk K; Kemel Y; Maio A; Belhadj S; Carlo MI; Latham A; Walsh MF; Dubard-Gault ME; Wang Y; Brannon AR; Salo-Mullen E; Sheehan M; Fiala E; Devolder B; Dandiker S; Mandelker D; Zehir A; Ladanyi M; Berger MF; Solit DB; Bandlamudi C; Ravichandran V; Bajorin DF; Stadler ZK; Robson ME; Vijai J; Seshan V; Offit K
Cancer Epidemiol Biomarkers Prev; 2022 Feb; 31(2):362-371. PubMed ID: 34810208
[TBL] [Abstract][Full Text] [Related]
35. Association Between Confocal Morphologic Classification and Clinical Phenotypes of Multiple Primary and Familial Melanomas.
Grazziotin TC; Alarcon I; Bonamigo RR; Carrera C; Potrony M; Aguilera P; Puig-Butillé JA; Brito J; Badenas C; Alós L; Malvehy J; Puig S
JAMA Dermatol; 2016 Oct; 152(10):1099-1105. PubMed ID: 27579522
[TBL] [Abstract][Full Text] [Related]
36. Multiple primary cancers associated with endometrial and ovarian cancers: An analysis based upon the Japan Autopsy Annual Database from 2002 to 2010.
Miki Y; Sugawara Y; Shibahara Y; Tsuji I; Sasano H; Ito K
J Obstet Gynaecol Res; 2019 May; 45(5):1012-1018. PubMed ID: 30734421
[TBL] [Abstract][Full Text] [Related]
37. The Association of
Wang X; Yu X; Krauthammer M; Hugo W; Duan C; Kanetsky PA; Teer JK; Thompson ZJ; Kalos D; Tsai KY; Smalley KSM; Sondak VK; Chen YA; Conejo-Garcia JR
Cancer Epidemiol Biomarkers Prev; 2020 Sep; 29(9):1792-1799. PubMed ID: 32611582
[TBL] [Abstract][Full Text] [Related]
38. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study.
Li T; Jia DD; Teng LS
Invest New Drugs; 2020 Oct; 38(5):1334-1341. PubMed ID: 32072356
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors.
Shao C; Li G; Huang L; Pruitt S; Castellanos E; Frampton G; Carson KR; Snow T; Singal G; Fabrizio D; Alexander BM; Jin F; Zhou W
JAMA Netw Open; 2020 Oct; 3(10):e2025109. PubMed ID: 33119110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
